심혈관계 질환, 특히 심방세동과 부정맥의 세계 만연이 증가하고 있으며, 고급 진단 및 치료 솔루션이 필요합니다. 특히 선진국에서는 고령화가 진행되어 전기생리학 수술에 대한 수요가 증가하고 있으며, 2024년에는 55억 7,000만 달러, 2031년에는 132억 9,000만 달러에 이를 것으로 예측됩니다.
또한 3D 매핑 시스템과 저침습 카테터 개발 등의 기술적 진보도 정확성과 환자의 예후를 향상시킴으로써 시장 확대를 뒷받침하고 있습니다. 더불어 헬스케어 지출 증가, 심장 건강에 대한 지식 향상, 카테터 어블레이션 수기의 이용 확대가 기존 경제권과 신흥 경제권 모두에서 시장 확대를 더욱 뒷받침하고 있어 2024년부터 2031년까지 CAGR 약 11.47%로 시장이 성장할 것으로 예측되고 있습니다.
전기생리학 시장 정의 및 개요
전기생리학이란 생체세포와 조직의 전기적 특성을 연구하는 학문이며, 특히 심장부정맥과 그 진단 및 치료에 중점을 두고 있습니다. 주요 용도로는 심방세동이나 심실빈박의 동정, 이상 심박을 치료하기 위한 카테터 어블레이션 등이 있습니다. 또, 페이스 메이커나 제세동기 등의 의료 기기의 심는 데에도 전기생리학이 이용되고 있습니다. 전기생리학의 미래는 낙관할 수 있을 것 같고, 3D 매핑, AI를 구사한 진단, 저침습 접근법 등의 진보로 정확도와 환자의 전귀가 개선될 가능성이 높습니다.
만성 질환, 특히 심혈관 질환의 유병률이 증가하는 것은 전기생리학(EP) 산업의 주요 촉진요인입니다. 심장 리듬 문제의 검출과 치료를 포함한 일렉트로 피지올로지는 심혈관 질환의 세계적 부담이 증가함에 따라 중요성이 증가하고 있습니다. 2024년 5월 발표된 세계보건기구(WHO)의 최신 보고서에 따르면 심혈관 질환은 여전히 세계 사망원인 1위이며 전체 사망의 31%를 차지하고 있습니다. 이 조사에 따르면 일반적인 심장 리듬 문제인 심방세동을 가진 사람의 수는 2020년부터 2023년 사이에 18% 증가했습니다.
2024년 3월 인도 정부는 만성 질환 치료에 대한 접근을 촉진하기 위해 고급 전기 물리학 장비를 갖춘 심장 전문 치료 센터 건설과 같은 공중 보건 인프라에 대한 투자를 발표했습니다. 이러한 법 정비와 기술 향상으로 만성 심장 질환 치료가 보다 친숙해지고, 전기생리학 시장의 성장 촉진요인이 되고 있습니다.
전기생리학 기기의 급등은 전기생리학 산업의 성장을 저해하는 중요한 요인입니다. 3D 매핑 시스템, 애블레이션용 카테터, 심장 모니터링 기기 등 일렉트로피질로지 기기에 채택된 첨단 기술은 고가인 경우가 많아 저소득층이나 소규모 헬스케어 시설에서는 이용하기 어렵습니다. 이 비용의 장벽이, 특히 헬스케어 예산이 한정되어 있는 저개발 국가에서, 이러한 기술의 보급을 방해하고 있습니다. 게다가 전기생리학적 치료에는 고액의 비용이 들기 때문에, 특히 보험 적용이나 상환 방법이 한정되어 있는 지역에서는, 많은 환자에게 있어서 치료법이 고액이 될 가능성이 있습니다.
특히 소규모 시설에서는 고가의 전기생리학적 기기의 입수와 유지에 드는 비용의 장벽이 투자의 방해가 될 수 있습니다. 그 결과 최신 진단 및 치료 기술의 이용이 지연되거나 제한될 수 있습니다. 그 결과 신흥국의 헬스케어 시스템은 전기생리학적 서비스에 대한 접근을 확대하는 데 있어 장애물에 직면하여 시장 전체의 성장을 둔화시킬 가능성이 있습니다. 기술의 비약적 진보와 수요의 고조가 기술혁신을 촉진할 가능성이 있는 한편, 가격설정의 문제를 해결하는 것은 보급과 시장의 확대를 보증하는데 있어서 매우 중요합니다.
The increasing global prevalence of cardiovascular illnesses, particularly atrial fibrillation and arrhythmias, which require sophisticated diagnostic and therapeutic solutions. An aging population, particularly in developed nations, contributes to higher demand for electrophysiological operations is fuelling the USD 5.57 Billion in 2024 and reachingUSD 13.29 Billion by 2031.
Technological improvements, such as the development of 3D mapping systems and minimally invasive catheters, are also fuelling market expansion by enhancing accuracy and patient outcomes. Additionally, increased healthcare expenditure, greater knowledge of heart health, and the expanding use of catheter ablation procedures are further boosting the market's expansion across both established and emerging economies fueling market expected to grow at aCAGR of about 11.47% from 2024 to 2031.
Electrophysiology Market: Definition/ Overview
Electrophysiology is the study of the electrical properties of biological cells and tissues, with a particular emphasis on cardiac arrhythmias and their diagnosis and treatment. Its principal applications include identifying atrial fibrillation and ventricular tachycardia, as well as performing catheter ablation procedures to treat abnormal heartbeats. Electrophysiology is also used to implant medical devices such as pacemakers and defibrillators. The future of electrophysiology seems optimistic, with advances in 3D mapping, AI-powered diagnostics, and minimally invasive approaches likely to improve precision and patient outcomes.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
The increasing prevalence of chronic diseases, particularly cardiovascular ailments, is a major driver of the Electrophysiology (EP) industry. Electrophysiology, which encompasses the detection and treatment of heart rhythm problems, is becoming increasingly important as the global burden of cardiovascular illnesses rises. In May 2024, According to the World Health Organization's most recent report, published, cardiovascular disease remains the top cause of mortality worldwide, accounting for 31% of all deaths. The survey stated that the number of persons living with atrial fibrillation, a common cardiac rhythm problem, grew by 18% between 2020 and 2023.
In March 2024, the Indian government announced investments in public health infrastructure to promote access to chronic illness treatments, including the construction of specialized cardiac care centers outfitted with sophisticated electrophysiology equipment. These legislative efforts, together with technology improvements, make chronic heart disease therapy more accessible and are significant drivers of the electrophysiology market's growth.
The rising high cost of electrophysiological devices is a crucial factor that may impede the growth of the electrophysiology industry. Advanced technology employed in these devices, like as 3D mapping systems, ablation catheters, and cardiac monitoring instruments, are frequently expensive, making them less accessible in low-income areas and tiny healthcare facilities. This cost barrier prevents the widespread use of these technologies, particularly in underdeveloped countries with limited healthcare budgets. Furthermore, the high cost of electrophysiological treatments may render treatment options expensive for many patients, particularly in areas with limited insurance coverage or reimbursement options.
The cost barrier of obtaining and maintaining expensive electrophysiological equipment can deter investment, particularly in smaller facilities. This, in turn, may result in the delayed or limited use of modern diagnostic and therapeutic technologies. As a result, healthcare systems in developing nations face hurdles in expanding access to electrophysiological services, potentially slowing overall market growth. While technology breakthroughs and rising demand may propel innovation, resolving pricing issues is crucial to guaranteeing widespread use and market
The increasing need for ablation catheters is driving the electrophysiology market forward. Ablation catheters are critical for the treatment of arrhythmias, particularly atrial fibrillation, and their upgraded characteristics, such as improved navigation and ablation technology, are pushing their widespread use. For instance, in July 2024, Medtronic got FDA approval for a new ablation catheter with improved precision and safety features, demonstrating the increased investment in this technology. The increasing prevalence of cardiovascular illnesses, as well as the desire for minimally invasive procedures, are major contributors to the high demand for ablation catheters. Furthermore, advances in catheter technology, such as those released by Abbott and Boston Scientific, are projected to maintain the segment's growing momentum.
In August 2024, the US Department of Health and Human Services launched a new project targeted at boosting access to advanced cardiac care, such as ablation therapy, which is likely to drive market growth. This program complements larger initiatives to enhance cardiovascular care and save healthcare costs through novel medicines. The combination of technology improvements, regulatory backing, and increased healthcare spending is expected to sustain and drive the growth of the electrophysiology market, with ablation catheters playing a critical part in this expansion.
However, laboratory gadgets are the market's fastest-growing category. This expansion is being driven by an increased emphasis on improving diagnostic capabilities and the demand for improved technologies in electrophysiology labs. As healthcare providers and research institutes invest in cutting-edge laboratory equipment to improve diagnosis accuracy and treatment outcomes, this market is quickly rising.
Rising sales from hospitals and cardiac centers are driving the electrophysiology market. These healthcare facilities are key purchasers of electrophysiology equipment, owing to the rising frequency of cardiac disorders and the demand for specialist treatment alternatives. For example, in June 2024, Boston Scientific established a strategic agreement with prominent institutions in North America to boost the usage of its latest electrophysiological equipment. This collaboration intends to improve patient outcomes and provide access to innovative electrophysiological treatments, suggesting a strong need in these crucial contexts.
In September 2024, the facilities for Medicare and Medicaid Services (CMS) revised its reimbursement policies to provide better coverage for electrophysiological procedures conducted in hospitals and specialist cardiac facilities. This legislative reform is expected to increase the use of advanced electrophysiological technology by lowering the cost obstacles for healthcare providers.
However, ambulatory surgery centers (ASCs) are the most rapidly expanding segment. ASCs provide a cost-effective and convenient option for outpatient procedures, such as electrophysiological tests and treatments. The transition to outpatient care, motivated by a desire to reduce healthcare costs and improve patient convenience, has resulted in growing use of electrophysiological services in ASCs. This tendency reflects a larger shift toward more efficient and accessible care approaches.
Country/Region-wise
Significant expenditures in medical technology in North America are generating tremendous growth in the electrophysiology (EP) sector. This trend is distinguished by increased investment for R&D, the use of modern technology, and supportive government policies. In May 2024, According to a report issued by the American Heart Association, investment in cardiovascular medical technology in North America reached USD 12.5 Billion in 2023, up 15% from the previous year, with electrophysiological devices accounting for 30% of this expenditure. This spike in financing has resulted in rapid advances in EP technology.
Furthermore, in April 2024, the Canadian government announced a multimillion-dollar investment in healthcare research and innovation, with a portion of the funding dedicated to enhancing cardiac care. These government measures, combined with private investments, are strengthening the North American electrophysiology market, positioning it as a key driver of growth and technological advancement in the area.
The increasing healthcare expenditure in the Asia Pacific region is expected to considerably boost the electrophysiology market. As governments and business sectors in China, India, and Japan increase healthcare expenditure, there is a greater emphasis on strengthening cardiac care infrastructure, including the use of modern electrophysiological technologies. In June 2024, the Chinese government announced a significant increase in healthcare funding, with a focus on hospital modernization and the integration of cutting-edge medical equipment, such as electrophysiological devices. This investment is likely to increase the availability and accessibility of electrophysiological techniques for diagnosing and treating heart arrhythmias, hence propelling the industry ahead in the region.
In May 2024, the Indian government announced a national healthcare expansion plan that will increase public spending on sophisticated medical technology, particularly those used in cardiac treatment. This effort aims to address the country's growing prevalence of cardiovascular disorders. When combined with increased private healthcare investment, such as the establishment of specialist cardiac centers equipped with cutting-edge electrophysiology technology in major urban areas, the region is experiencing a large increase in demand for these technologies.
The competitive landscape of the electrophysiology market is characterized by a mix of regional and emerging players alongside established companies. These smaller or regional firms focus on specialized areas such as niche cardiac diagnostic tools, catheter-based treatments, and mapping systems, catering to specific needs in various regions. Many are engaged in developing advanced technologies, such as AI-driven diagnostic tools and minimally invasive solutions, to compete with larger companies. Additionally, strategic partnerships, mergers, and acquisitions are common as these players seek to expand their product portfolios and geographical reach.
Some of the prominent players operating in the electrophysiology market include:
Acutus Medical, Inc.
APN Health LLC
Asahi Kasei Corp.
BIOTRONIK SE and Co. KG
Boston Scientific Corp.
CathRx Pty Ltd.
EP Solutions SA
EPMap System GmbH
GE Healthcare Technologies, Inc.
Imricor Medical Systems, Inc.
Japan Lifeline Co. Ltd.
Johnson and Johnson
In May 2024, Philips introduces a new electrophysiological imaging platform with AI-driven analytics to improve diagnostic accuracy. This platform is intended to help electrophysiologists diagnose and treat complicated arrhythmias more efficiently.
In April 2024, The Stereotaxis announced a significant update to its robotic navigation system for electrophysiological operations. The updated system improves automation and precision, with the goal of reducing procedural time and increasing safety.
In February 2024, The Medtronic introduced a new range of electrophysiology diagnostic catheters including improved sensing technologies. These catheters are intended to provide more detailed and accurate electrophysiological data, hence enabling better clinical decision-making.